Validated tumor tissue samples for cancer research
CancerSeq™ FFPE tissues from AMSBIO (Oxford, UK) are pre-screened tumor tissue samples for single nucleotide polymorphisms (SNP’s), insertions and deletions plus copy number variations (CNVs) using targeted Next Generation Sequencing to identify key mutations and mutational hotspots.
A major focus of cancer research is gaining insights into the complex mechanisms driving tumor development. While traditional cancer cell lines or genetically altered cell lines are commonly used as in vitro tumor models, they do not capture the diverse genetic variances present in real tumor tissues, which carry multiple mutations rather than just one or two.
CancerSeq™ tissues, derived from real tumor samples, are critical for studying the full complexity of clinical cancer biology. Available as FFPE curls, slides, and blocks, CancerSeq™ samples are prepared from genomic DNA extracted from authentic tumor tissues, enabling researchers to explore cancer in a more accurate and relevant way.
Validated using the most advanced Next Generation Sequencing instruments, CancerSeq™, CancerSeq™ Plus and CancerSeq™ AMS tissue samples are delivered with the mutation and variation data for up to 67 cancer-related genes including BRAF, KRAS, EGFR, ALK and TP53. Additionally, details of the tissue donor clinical histories and tumor type can also be supplied on request.
CancerSeq™ tissue samples are proven in research applications including validation of cancer marker mutation related drug candidates; controls for genotyping; companion diagnostic assay development; IHC and in-situ hybridization assays: cellular localization of tissue specific mRNA and protein expression as well as isolation of DNA and RNA with specific mutation profiles.
For further information please visit https://www.amsbio.com/cancerseq-paraffin-tissue-samples/ or contact AMSBIO to discuss your specific cancer research needs on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].
About AMSBIO
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.
This content was provided by AMSBIO.
